<DOC>
	<DOCNO>NCT00445185</DOCNO>
	<brief_summary>The current extension study assess persistence anti-HBs antibody Months 12 , 24 36 primary vaccination Henogen 's HBV vaccine Fendrix™ . This protocol post deal objective &amp; outcome measure extension phase Months 12 , 24 36 . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00291941 ) .</brief_summary>
	<brief_title>Study Evaluating Persistence Anti-HBs Antibodies Uraemic Patients Receiving Henogen 's HBV Vaccine , Fendrix™</brief_title>
	<detailed_description>Subjects receive complete full vaccination Henogen HBV adjuvanted vaccine Fendrix™ participate persistence study three long-term time point ( 12 , 24 36 month first dose primary vaccination ) . Blood sample do time point measure immune persistence .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Written inform consent obtain subject/ parent/ guardian subject . Subjects complete full course primary vaccination . Immunosuppression cause administration parenteral steroid chemotherapy . Any confirm suspected human immunodeficiency virus ( HIV ) infection .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Dialysis</keyword>
	<keyword>Pre-dialysis</keyword>
	<keyword>Hepatitis B vaccine</keyword>
	<keyword>vaccine</keyword>
</DOC>